New Transporting Solution in Parathyroid Allotransplantation

The Effects of Cold Ischemia Time With a New Transporting Solution to Parathyroid Cell Viability and Calcium Sensing Receptor in Parathyroid Allotransplantation

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02978287

Enrollment

Registered

2016-11-30

Start date

2016-09-30

Completion date

2016-12-31

Last updated

2016-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parathyroid Allotransplantation

Keywords

Calcium sensing receptor, Parathyroid cell viability, Parathyroid allotransplantation, Transporting solution

Brief summary

The aim of this study is to measure of the parathyroid cell viability and the the amount of calcium sensing receptor of the parathyroid cells which were placed into a new transportation solution (BAVU solution) for parathyroid allotransplantation.

Detailed description

The cold ischemia of organs, has harmful effects on the tissues due to oxidative stress and inflammation. This is physiopathologically defined as ischaemia/re-perfusion injury (IRI) in organ transplantation. Parathyroid allotransplantation has an increased popularity at the last decade. But the cold ischemia due to transportation of the transplant tissue is a very important problem. Calcium sensing receptor plays a crucial role in regulating Parathormone secretion which means controlling of the calcium-dependent systemic ion homeostasis. The investigators developed a new tissue transporting solution for parathyroid allotransplantation and the investigators measured the parathyroid cell viability and the the amount of calcium sensing receptor of the parathyroid cells at the 0., 6., 12. and 24. hours of the parathyroid cells which were placed into our new solution.

Interventions

DRUGBAVU Solution

Tissue preservation solution for transplantation

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients who have parathyroid hyperplasia due to chronic renal failure

Exclusion criteria

* Patients who refused to join to the study * Patients younger than 18 years and older than 80 years. * Patients who have hepatitis B, * Patients who have hepatitis C, * Patients who have human immunodeficiency virus (HIV)

Design outcomes

Primary

Measure	Time frame	Description
Cell viability of Parathyroid cells	0 hour	The investigators will measure the viability of Parathyroid cells at 0 hour at the BAVU solution

Countries

Turkey (Türkiye)

Contacts

Primary ContactErhan Aysan, Prof. M.D.

erhanaysan@hotmail.com+905322034879

Backup ContactUfuk Oguz Idiz, M.D.

oguzidiz@hotmail.com+905062044714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026